H.C. Wainwright analyst Yi Chen believes ProPhase Labs needs a near-term capital infusion to fund operations into the second half of 2024. The company’s cash inflows may be partly generated through collection of account receivable, but there is no visibility on the amount or timeline of successful collection, the analyst tells investors in a research note. As a result, the firm updated its rating on the shares to under review from Buy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRPH:
- ProPhase Labs sees significant sequential improvement in revenues going forward
- ProPhase Labs reports 2023 EPS (98c) vs. $1.02 last year
- ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives
- PRPH Earnings this Week: How Will it Perform?
- PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024
